NOV 22, 2020 11:20 AM PST

Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD

WRITTEN BY: Annie Lennon

Researchers from St. Michael’s Hospital in Toronto have found that two synthetic cannabinoids available on prescription are linked to an increased risk of death and hospitalization in older patients with chronic obstructive pulmonary disease (COPD). 

For the study, the researchers looked at data from over 4,000 people with COPD in Ontario aged over 66 between 2006 and 2016. The patients were divided into two groups. One group used dronabinol or nabilone, synthetic cannabinoids with a similar chemical structure to THC often prescribed to treat COPD symptoms such as pain, difficulties falling asleep, and breathlessness. Meanwhile, the other group did not use these cannabinoids. 

In the end, the researchers found that while patients who used either cannabinoid were no more likely to be hospitalized for COPD or pneumonia than those in the other group, they were more likely to die of any cause. This was especially true for those who received high doses. All in all, these patients were 178% more likely to be hospitalized for COPD and pneumonia and 231% more likely to die of any cause. 

“Our study results do not mean that cannabinoid drugs should be never used among older adults with COPD,” says Dr. Nicholas Vozoris, lead author of the study. “Rather, our findings should be incorporated by patients and physicians into prescribing decision-making.”

While the researchers say that their findings show a negative association between older adults with COPD and synthetic cannabinoids, further research is needed to confirm their results. Nevertheless, as older adults are increasingly using cannabinoid-based drugs to treat COPD, the researchers say care should be taken when prescribing the drugs and for patients and physicians alike to have a clear understanding of their potential side effects. 

 

Sources: BMJMarijuana Business Daily

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
MAY 06, 2021
Cannabis Sciences
New CBD Analog Outperforms Regular CBD for Pain Relief
MAY 06, 2021
New CBD Analog Outperforms Regular CBD for Pain Relief
Researchers from Temple University Health System have found that a novel cannabidiol (CBD) analog can reverse pain sensi ...
JUN 02, 2021
Cannabis Sciences
Can CBD Help Manage Symptoms of Diabetes?
JUN 02, 2021
Can CBD Help Manage Symptoms of Diabetes?
As cannabidiol (CBD) products become increasingly mainstream, more people are using them to manage symptoms for chronic ...
JUN 28, 2021
Cannabis Sciences
Can Smoking Cannabis Cause COPD?
JUN 28, 2021
Can Smoking Cannabis Cause COPD?
Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term for chronic lung conditions including chronic bronchiti ...
JUL 12, 2021
Cannabis Sciences
How does CBD Affect Heart Arrhythmia?
JUL 12, 2021
How does CBD Affect Heart Arrhythmia?
Heart arrhythmias happen when the heart beats too fast, too slow, or irregularly. According to the Centers for Dise ...
SEP 01, 2021
Health & Medicine
Does Regular Cannabis Affect Brain Function? Sometimes in a Good Way
SEP 01, 2021
Does Regular Cannabis Affect Brain Function? Sometimes in a Good Way
With cannabis now legal in many parts of the world, an increasing number of people now count as regular users of the dru ...
SEP 30, 2021
Cannabis Sciences
Concerning New Evidence Regarding Cannabis Use During Pregnancy
SEP 30, 2021
Concerning New Evidence Regarding Cannabis Use During Pregnancy
According to data from a National Vital Statistics Report published in March 2021, the percentage of infants born with a ...
Loading Comments...